Par Drugs & Chemicals Ltd
Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals[1]
- Market Cap ₹ 110 Cr.
- Current Price ₹ 89.5
- High / Low ₹ 348 / 81.0
- Stock P/E 11.4
- Book Value ₹ 86.5
- Dividend Yield 0.00 %
- ROCE 18.4 %
- ROE 13.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.04 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.27 | 33.25 | 33.26 | 48.77 | 42.38 | 46.33 | 55.85 | 60.75 | 75.07 | 95.75 | 95.64 | 100.97 | 98.42 | |
| 20.01 | 25.88 | 26.07 | 40.31 | 34.40 | 38.13 | 46.41 | 44.74 | 58.82 | 77.55 | 72.82 | 81.47 | 84.94 | |
| Operating Profit | 7.26 | 7.37 | 7.19 | 8.46 | 7.98 | 8.20 | 9.44 | 16.01 | 16.25 | 18.20 | 22.82 | 19.50 | 13.48 |
| OPM % | 26.62% | 22.17% | 21.62% | 17.35% | 18.83% | 17.70% | 16.90% | 26.35% | 21.65% | 19.01% | 23.86% | 19.31% | 13.70% |
| 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.09 | 0.10 | 2.18 | 0.18 | 0.24 | 0.24 | 2.15 | 3.38 | |
| Interest | 3.91 | 3.86 | 3.57 | 2.50 | 2.33 | 1.96 | 0.79 | 0.64 | 0.45 | 0.13 | 0.11 | 0.08 | 0.10 |
| Depreciation | 2.17 | 2.33 | 2.65 | 2.82 | 3.14 | 3.04 | 2.76 | 2.82 | 3.28 | 3.23 | 3.44 | 3.65 | 3.67 |
| Profit before tax | 1.21 | 1.22 | 1.01 | 3.18 | 2.55 | 3.29 | 5.99 | 14.73 | 12.70 | 15.08 | 19.51 | 17.92 | 13.09 |
| Tax % | 39.67% | 27.05% | 58.42% | 42.14% | 41.57% | 23.71% | 20.53% | 21.11% | 27.48% | 24.87% | 25.73% | 25.50% | |
| 0.72 | 0.89 | 0.42 | 1.85 | 1.50 | 2.51 | 4.76 | 11.61 | 9.21 | 11.33 | 14.50 | 13.36 | 9.69 | |
| EPS in Rs | 1.33 | 1.65 | 0.78 | 3.43 | 2.78 | 2.79 | 3.87 | 9.44 | 7.49 | 9.21 | 11.78 | 10.86 | 7.88 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 32.30% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 13% |
| 3 Years: | 10% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 22% |
| 3 Years: | 11% |
| TTM: | -47% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | -17% |
| 1 Year: | -69% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 17% |
| 3 Years: | 16% |
| Last Year: | 14% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.70 | 2.70 | 2.70 | 2.70 | 2.70 | 4.48 | 6.15 | 6.15 | 12.30 | 12.30 | 12.30 | 12.30 | 12.30 |
| Reserves | 7.71 | 8.58 | 8.91 | 10.75 | 12.25 | 24.55 | 34.46 | 46.06 | 47.57 | 58.93 | 73.33 | 86.67 | 94.13 |
| 44.12 | 38.46 | 36.49 | 30.55 | 28.87 | 11.58 | 6.01 | 8.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 6.86 | 8.85 | 9.93 | 12.05 | 10.12 | 10.66 | 13.49 | 15.86 | 18.82 | 17.64 | 15.98 | 20.42 | 21.09 | |
| Total Liabilities | 61.39 | 58.59 | 58.03 | 56.05 | 53.94 | 51.27 | 60.11 | 76.39 | 78.69 | 88.87 | 101.61 | 119.39 | 127.52 |
| 47.06 | 45.11 | 42.61 | 41.53 | 39.04 | 36.34 | 34.40 | 29.91 | 34.10 | 38.45 | 41.31 | 38.91 | 37.70 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 | 4.52 | 0.25 | 0.25 | 0.03 | 0.00 | 0.07 |
| Investments | 0.00 | 0.00 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.01 | 0.01 | 0.01 | 0.01 | 25.07 | 26.72 |
| 14.33 | 13.48 | 15.36 | 14.46 | 14.84 | 14.87 | 24.91 | 41.95 | 44.33 | 50.16 | 60.26 | 55.41 | 63.03 | |
| Total Assets | 61.39 | 58.59 | 58.03 | 56.05 | 53.94 | 51.27 | 60.11 | 76.39 | 78.69 | 88.87 | 101.61 | 119.39 | 127.52 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.30 | 8.94 | 6.53 | 9.17 | 4.32 | 2.10 | 7.69 | 12.09 | 7.62 | 13.38 | 20.25 | 16.16 | |
| -6.17 | -0.34 | -0.17 | -1.70 | -0.60 | -0.25 | -1.46 | 0.05 | -3.02 | -7.34 | -5.84 | -25.24 | |
| 1.58 | -9.31 | -5.46 | -8.38 | -3.67 | -1.88 | 1.11 | 1.65 | -9.55 | 0.00 | 0.00 | 0.00 | |
| Net Cash Flow | 0.71 | -0.70 | 0.90 | -0.91 | 0.05 | -0.03 | 7.35 | 13.78 | -4.96 | 6.04 | 14.41 | -9.08 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 103.87 | 82.55 | 80.99 | 60.70 | 75.10 | 67.12 | 80.84 | 74.80 | 89.80 | 64.69 | 52.32 | 60.41 |
| Inventory Days | 128.93 | 111.47 | 158.37 | 69.12 | 82.85 | 81.47 | 45.07 | 50.05 | 59.65 | 48.69 | 45.15 | 58.49 |
| Days Payable | 170.68 | 184.47 | 182.78 | 134.77 | 107.08 | 93.62 | 95.69 | 112.10 | 135.01 | 73.22 | 57.90 | 104.24 |
| Cash Conversion Cycle | 62.12 | 9.55 | 56.58 | -4.96 | 50.88 | 54.97 | 30.22 | 12.75 | 14.45 | 40.16 | 39.58 | 14.65 |
| Working Capital Days | 102.13 | 61.25 | 65.52 | -45.95 | -26.10 | 13.31 | 39.15 | 24.33 | 60.73 | 50.36 | 40.19 | 38.72 |
| ROCE % | 9.74% | 9.36% | 12.31% | 11.11% | 12.44% | 15.50% | 24.97% | 21.84% | 22.99% | 25.00% | 18.35% |
Documents
Announcements
-
Copy of Newspaper Publication
14 November 2025 - Published standalone unaudited Q2/H1 results (ended Sep 30, 2025): total income Rs2,865.89 lakh, PAT Rs412.96 lakh.
-
Updates
13 November 2025 - Approved Q2/H1 FY26 unaudited results (30 Sep 2025): Qtr revenue Rs2,865.89L, profit Rs412.96L.
-
Outcome of Board Meeting
13 November 2025 - Board approved unaudited Q2/H1 (ended 30‑Sep‑2025) results: Q revenue ₹2,865.89L, H1 revenue ₹5,470.53L; limited review.
-
Outcome of Board Meeting
13 November 2025 - Unaudited Q2/H1 FY26 results: Q revenue Rs2,865.89L; H1 revenue Rs5,470.53L; Q PAT Rs412.96L; approved 13/11/2025.
-
Outcome of Board Meeting
13 November 2025 - Board approved unaudited financial results for quarter and half year ended 30 September 2025; limited review attached.
Annual reports
Concalls
-
Jun 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Mar 2023TranscriptNotesPPT
-
Mar 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Dec 2021TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Sep 2019TranscriptNotesPPT
Business Overview:[1]
PACL manufactures Active Pharma Ingredients for domestic and exports markets, they have a portfolio of 15 APIs and 10 Fine Chemicals. It produces the entire range of products in the Antacid Molecules segment